TLR7 and neoplasm: Taken together these results suggest that the synergy between oral and topical IMQ is based on type I IFN induction in pDCs by oral IMQ, followed by upregulation of TLR7/8 on myeloid cells such as DCs, possibly sensitizing these immune cells to topical TLR7/8 agonist treatment at tumor sites.